ÂÜÀòÂÒÂ×

Kevin Lalande is Founding Managing Director and Chief Investment Officer of ³§²¹²Ô³Ùé, a multi-strategy investment partnership with over $800 million in capital under management in two separate strategies.

³§²¹²Ô³Ùé Ventures is a healthcare and life science venture capital strategy founded in 2006 that manages over a half-billion dollars across three funds and 30+ portfolio companies. Over the last 15 years, the partners of ³§²¹²Ô³Ùé Ventures have helped create, build, and finance a valuable portfolio of innovative new healthcare companies including LDR Medical (Nasdaq: LDRH, later acquired by Zimmer Biomet), Explorys (IBM Corp), AbVitro (Bristol Myers Squibb), Molecular Templates (Nasdaq:MTEM), Millipede Medical (Boston Scientific), TVA Medical (Becton Dickinson), and Claret Medical (Boston Scientific).

³§²¹²Ô³Ùé Capital is a systematic machine learning hedge fund strategy that began trading capital in 2015 after three years of research and development. Kevin conceived the investment strategy, designed the original MindRank algorithms, and assembled an experienced team to help drive this line of business.

Before ³§²¹²Ô³Ùé, Kevin spent seven years as an investment professional with Austin Ventures, a venture capital firm with $4 billion under management. Prior to Austin Ventures, he was a Management Consultant with McKinsey & Company. Before McKinsey, he founded, built and sold three internet-based companies in the 1990s.

Kevin received a bachelor’s degree with honors in Electrical & Computer Engineering, an MBA with highest distinction from Harvard Business School, where he was both a Baker Scholar and a Siebel Scholar, and a graduate certificate in Artificial Intelligence from Stanford University.